Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17190952.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
Medical subject headings
- Botulinum Toxins
- Drug Resistance
- Torticollis
Anatomy
- cervical spine